COMMUNIQUÉS West-GlobeNewswire

OneMedNet Expands Into $1.5B Healthcare Data Annotation Market With MedCase
24/09/2025
MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with [...]
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
24/09/2025
VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Alira Health Becomes First Platinum CRO Partner of the Wound Care Collaborative Community, Expanding Ongoing Work to Advance Wound Healing Innovation
24/09/2025
FRAMINGHAM, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Alira Health announced today that it has become the first Platinum CRO Partner of the Wound Care Collaborative Community (WCCC), demonstrating its continued [...]
WORK Medical Technology Group LTD Partners with Hong Kong Web3.0 Standardization Association to Collaborate on Blockchain and RWA Innovations
24/09/2025
Hangzhou, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
Berry Street Earns Recognition from the American Diabetes Association
24/09/2025
The ADA’s Education Recognition Program certification ensures quality diabetes education and support for people living with diabetes. NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Today, the American Diabetes Association [...]
TOMI Environmental Solutions Announces Specialized Service Provider for Healthcare and Mold Remediation
24/09/2025
FREDERICK, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced a new service [...]
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
24/09/2025
Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and TerThera BV , a leading provider of GMP-grade [...]
Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)
24/09/2025
U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of unmet need in 3L mCRC CAMBRIDGE, United Kingdom and NEW YORK, September 24, 2025 – Artios [...]
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
24/09/2025
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than [...]
Communiqué de presse : Mise en ligne du document "Q3 2025 Aide mémoire"
24/09/2025
Mise en ligne du document «Q3 2025 Aide mémoire » Paris, France, le 24 septembre 2025 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q3 2025 Aide [...]
Press release: Availability of the Q3 2025 Aide mémoire
24/09/2025
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025 . Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third quarter 2025 ( [...]
Dimora PHMB Skin and Wound Cleanser - Gentle for Kids, Trusted by Parents
24/09/2025
Dimora PHMB Skin and Wound Cleanser: Gentle for Kids, Trusted by Parents SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Dimora Medical is proud to introduce its newest innovation, the Dimora PHMB Skin and Wound [...]
Communiqué de presse : Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique
24/09/2025
Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique Le fonds restera axé sur les [...]
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24/09/2025
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, [...]
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health
24/09/2025
The studies established the lead asset to be well tolerated in healthy volunteers at all doses with a good safety profile SYT-510 demonstrated penetration in the central nervous system and a pharmacodynamic effect on [...]
Correction d’une erreur matérielle relative au nombre total de droits de vote et d’actions composant le capital
24/09/2025
Correction d’une erreur matérielle relative au nombre total de droits de vote et d’actions composant le capital Mise au Point Face aux Accusations Infondées Nantes, le 24 septembre 2025 à 8 h 00 CET –OSE [...]
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
24/09/2025
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital Clarification in Response to Unfounded Accusations NANTES, France – September 24, 2025, 8:00 a.m. CET [...]
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
24/09/2025
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMS One-year data reinforce [...]
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
24/09/2025
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* [...]

Pages